Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

Abstract Background Early detection of oesophageal cancer improves outcomes; however, the optimal strategy for identifying patients at increased risk from the pre-cancerous lesion Barrett’s oesophagus (BE) is not clear. The Cytosponge, a novel non-endoscopic sponge device, combined with the biomarke...

Full description

Bibliographic Details
Main Authors: Judith Offman, Beth Muldrew, Maria O’Donovan, Irene Debiram-Beecham, Francesca Pesola, Irene Kaimi, Samuel G. Smith, Ashley Wilson, Zohrah Khan, Pierre Lao-Sirieix, Benoit Aigret, Fiona M. Walter, Greg Rubin, Steve Morris, Christopher Jackson, Peter Sasieni, Rebecca C. Fitzgerald, on behalf of the BEST3 Trial team
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Cancer
Subjects:
Heartburn
Acid reflux
Early detection
Oesophageal cancer
Biomarker
Endoscopy
Online Access:http://link.springer.com/article/10.1186/s12885-018-4664-3

Internet

http://link.springer.com/article/10.1186/s12885-018-4664-3

Similar Items